Head and Neck Cancer
An Introduction to Head and Neck Cancer
More than 60% of patients with squamous cell cancer of the head and neck present with stage III or IV disease, which has a poor prognosis. However, recent advances have improved outcomes. Chemoradiotherapy is often successful in first-line treatment and more precisely targeted radiotherapy using intensity-modulated radiation therapy, molecular imaging-guided therapy, adaptive therapy and proton beam therapy is expected to decrease the long-term toxicity of radiotherapy. However, recurrent or metastatic disease often develops. Immune checkpoint inhibitors targeting programmed death ligand 1 (PD-L1) have proved effective for a minority of patients in this setting and are being investigated in earlier treatment settings.
Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Head and Neck Cancer Content
What’s on the horizon to tackle unmet needs in recurrent/metastatic SCCHN?
Experts consider current unmet needs and possible future treatment directions for R/M SCCHN.
- Recall unmet treatment needs for patients with recurrent/metastatic SCCHN
- Discuss the rationale and latest data for immunotherapy-based treatments in development for recurrent/metastatic SCCHN
- Evaluate the rationale and latest data for investigational targeted therapies for recurrent/metastatic SCCHN
Preventing HPV-associated cancer by maximizing vaccine uptake
Watch three experts discuss the importance of HPV vaccination in preventing HPV-associated cancers, and how to maximize vaccine uptake
- Illustrate the importance of vaccinating children and adolescents against HPV to prevent cancer in adulthood
- Describe recent guidelines and best practices for HPV vaccine eligibility and administration
- Appraise the barriers to HPV vaccine uptake in different populations and how they may be overcome
Clinical Utility of Human Papillomavirus Circulating Tumour DNA in Human Papillomavirus-positive Head and Neck Squamous Cell Carcinomas
touchREVIEWS in Oncology & Haematology. 2022;18(2):125-9 DOI: https://doi.org/10.17925/OHR.2022.18.2.125
Head and neck squamous cell carcinomas (HNSCCs) encompass a diverse group of tumours arising from the nasopharynx, oral cavity, oropharynx, hypopharynx and larynx. Tobacco and alcohol abuse are risk factors for the development of HNSCC, particularly oral cavity, hypopharyngeal and laryngeal cancers, whereas Epstein–Barr virus (EBV) and human papillomavirus (HPV) can mediate tumourigenesis in nasopharyngeal […]
Makoto Tahara, ESMO 2022: 5-year results from KEYNOTE-048 – Pembrolizumab for treatment of recurrent/metastatic head and neck squamous cell carcinoma
Long-term follow-up (4 years) of the phase 3 KEYNOTE-048 (NCT02358031) study continued to demonstrate survival benefit with pembrolizumab monotherapy and pembrolizumab + chemotherapy vs EXTREME in first-line recurrent/metastatic head and neck squamous cell carcinoma. Dr Makoto Tahara(Cliniques Universitaires Saint-Luc, Brussels, Belgium) joins touchONCOLOGY to discuss 5 years of follow-up in patients from KEYNOTE-048, and the […]
Jean-Pascal Machiels, ESMO 2022: Phase 3 KEYNOTE-412 study – efficacy and safety of pembrolizumab + chemoradiation therapy in locally advanced head and neck squamous cell carcinoma
Pembrolizumab is currently approved as monotherapy or in combination with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma. Dr Jean-Pascal Machiels (Cliniques Universitaires Saint-Luc, Brussels, Belgium) joins touchONCOLOGY to discuss the current limitations in treatment options, and the phase 3 KEYNOTE-412 study investigating the efficacy and safety of pembrolizumab + chemoradiation therapy (CRT) vs […]
Jean-Pascal Machiels, ESMO 2022: Highlights in head and neck cancer
Dr Jean-Pascal Machiels (Cliniques Universitaires Saint-Luc, Brussels, Belgium) joins touchONCOLOGY to discuss clinical trial highlights in head and neck cancer presented at EMSO 2022. Questions: What are the hot topics and highlights in head and neck cancers from ESMO 2022? Disclosures: Jean-Pascal Machiels is an Advisory board member or speaker with honoraria (managed by my […]
Navigating the challenges of treatment provision in recurrent/metastatic head and neck squamous cell carcinoma
Three experts consider the optimal management of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).
- Recall the latest data for the treatment of recurrent/metastatic HNSCC
- Use the latest data to select the most appropriate treatment for patients with recurrent/metastatic HNSCC
- Explain the importance of establishing patient preferences and priorities in treatment decision-making
Optimizing the patient journey in CSCC through multidisciplinary collaboration
In this activity, leading experts discuss optimal approaches for the management of patients with CSCC and consider how effective multidisciplinary collaboration can contribute to improved outcomes.
- Define multidisciplinary best practices for diagnostic workup of cutaneous squamous cell carcinoma (CSCC) and identification of risk factors influencing prognosis
- Outline interdisciplinary eligibility criteria for surgery and radiotherapy in patients with CSCC
- Determine the optimal use of systemic therapies in patients with unresectable locally advanced or metastatic CSCC and the role of the multidisciplinary tumour board in sharing clinical decisions in cancer care
Personalized treatment of RET-altered thyroid cancers: What is the value of biomarker testing and targeted therapies?
Leading experts explain the value of biomarker testing and targeted therapies for the personalized treatment of RET-altered thyroid cancers
- Distinguish between different types of thyroid cancers and describe therapies that are appropriate for their management
- Plan a personalized approach to treatment of RET-altered thyroid cancers, including use of biomarker testing and novel targeted therapies
- Evaluate the clinical trial data for novel targeted therapies for RET-altered thyroid cancers and apply it to clinical practice